Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Many Americans support prohibiting commercials for prescription drugs on television. But enacting that ban could be ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Amgen Inc. closed 18.42% short of its 52-week high of $346.85, which the company achieved on July 25th.

Three years after beginning construction in southwestern Wake County, the pharmaceutical company Amgen celebrated the ...

Amgen Inc. closed 19.88% short of its 52-week high of $346.85, which the company reached on July 25th.

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...

Amgen Inc (AMGN) stock saw a decline, ending the day at $280.3 which represents a decrease of $-2.65 or -0.94% from the prior close of $282.95. The stock opened at $280.13 and touched a low of $279.97 ...